Ipragliflozin first SGLT2 inhibitor to get Japan nod
This article was originally published in Scrip
Executive Summary
Astellas's ipragliflozin has become the first sodium glucose co-transporter-2 (SGLT2) inhibitor to be approved in Japan, receiving final marketing clearance as Suglat from the country's ministry of health, labour and welfare for the treatment of type 2 diabetes.